INTERNATIONAL JOURNAL OF EXPLORING EMERGING TRENDS IN ENGINEERING
Peer-Reviewed, Refereed, Indexed and International Journal, https://ijoeete.com/
|ISSN No. 2394-0573 |Volume: 11, Issue: 3 | July – September 2024

MICROBIAL BIOTRANSFORMATION OF ORGANIC COMPOUNDS INTO HIGH-VALUE PHARMACEUTICAL DERIVATIVES: ISOLATION, OPTIMIZATION, AND BIOACTIVITY EVALUATION

[1] Vivek Upadhyay, [2]Prof. (Dr.) Anuja Chouhan
[1]Research Scholar, [2]Supervisor
[1-2] Department of Chemistry, Asian International University, Imphal West, Manipur, India

Abstract
Microbial biotransformation offers a sustainable approach for converting structurally complex organic compounds into pharmaceutical derivatives that may be difficult to obtain through conventional chemical synthesis. The present study proposes the isolation and screening of environmental microorganisms capable of transforming papaverine into structurally modified derivatives with enhanced pharmacological potential. Fungal and bacterial strains will be isolated from medicinal-plant rhizosphere soils, compost, decaying plant material, and endophytic tissues. Purified isolates will be screened in submerged cultures containing papaverine as the model substrate. Transformation products will initially be detected through thin-layer chromatography and high-performance liquid chromatography, followed by liquid chromatography–mass spectrometry. The most productive isolate will be identified through internal transcribed spacer or 16S ribosomal RNA gene sequencing. Process variables, including pH, temperature, substrate concentration, inoculum size, agitation rate, and incubation period, will be optimized using response surface methodology. Major metabolites will be purified through chromatographic techniques and structurally characterized by high-resolution mass spectrometry and one- and two-dimensional nuclear magnetic resonance spectroscopy. Pharmaceutical potential will be evaluated through α-glucosidase, pancreatic lipase, protein tyrosine phosphatase 1B, antioxidant, antimicrobial, and preliminary cytotoxicity assays. Previous research has demonstrated that fungal transformation of papaverine can produce hydroxylated, demethylated, reduced, oxidized, and N-oxide derivatives with potentially improved enzyme-inhibitory properties. The proposed study integrates microbial isolation, metabolite discovery, statistical process optimization, structural characterization, and biological evaluation within a single experimental platform. It is expected to identify new microbial biocatalysts and potentially valuable papaverine derivatives for further pharmaceutical development.

Keywords: microbial biotransformation; papaverine; pharmaceutical derivatives; filamentous fungi; process optimization; response surface methodology; α-glucosidase; pancreatic lipase; bioactivity

1. Introduction

The development of pharmaceutical derivatives commonly requires selective modification of chemically complex molecules. Conventional organic synthesis can achieve such modifications, but it may require multiple reaction stages, hazardous reagents, extreme reaction conditions, and expensive purification procedures. These limitations become particularly important when hydroxylation, glycosylation, demethylation, oxidation, reduction, or stereoselective modification is required at chemically inaccessible positions. Microbial biotransformation employs living microbial cells or their enzymes to convert a parent compound into structurally related metabolites. Microbial systems can perform regioselective and stereoselective reactions under comparatively mild conditions. Bacteria, yeasts, and filamentous fungi possess oxidoreductases, cytochrome P450 monooxygenases, glycosyltransferases, hydrolases, methyltransferases, and other enzymes that can modify pharmaceutical and natural-product scaffolds. Whole-cell systems are particularly useful because the microorganism can regenerate cofactors required for enzyme activity.

Recent experimental studies demonstrate the pharmaceutical relevance of this approach. Whole-cell cytochrome P450 biocatalysts have produced hydroxylated flavonoids such as eriodictyol, dihydroquercetin, luteolin, and hydroxylated isoflavones. Fungal transformation has also generated glycosylated flavanones with altered antimicrobial and anticancer potential. In another study, transformation of resveratrol and piceatannol by *Beauveria*

bassiana generated new methylglucosides, one of which demonstrated GPR119 agonistic activity and stimulated insulin secretion. Fungal biotransformation is also applicable to structurally complex terpenoids and alkaloids. Transformation of cyclocephagenol by an endophytic *Alternaria* strain produced metabolites that were subsequently examined for neuroprotective activity. Similarly, microbial modification of papaverine generated seven derivatives through reduction, demethylation, hydroxylation, oxidation, and N-oxidation. The products were characterized through mass spectrometry and one- and two-dimensional nuclear magnetic resonance spectroscopy. Some transformed products, particularly papaverinol-N-oxide, showed stronger predicted interactions with α-glucosidase, pancreatic lipase, and protein tyrosine phosphatase 1B than the parent compound.

Papaverine is an isoquinoline alkaloid with a chemically modifiable aromatic and heterocyclic structure. Its methoxy groups, isoquinoline nucleus, and side-chain region provide several possible sites for microbial oxidation, demethylation, reduction, and hydroxylation. Previous researchers screened 50 fungal strains and identified several organisms capable of generating distinct papaverine metabolites, demonstrating that transformation capacity differs substantially among microbial species. Despite these advances, many studies depend on microorganisms obtained from established culture collections. Comparatively less attention has been given to the systematic isolation of locally adapted microorganisms from medicinal-plant environments, followed by integrated screening, statistical optimization, product purification, and biological evaluation. Environmental isolates may possess metabolic pathways that are absent or weakly expressed in conventional laboratory strains.

2. Research Problem

Papaverine and other structurally complex organic compounds possess considerable pharmaceutical potential, but their chemical modification can be difficult because conventional synthesis may provide limited regioselectivity and require several reaction and purification stages. Although selected microbial strains can convert papaverine into structurally diverse metabolites, the biotransformation potential of environmental microorganisms remains insufficiently explored. Furthermore, microbial conversion yields are frequently affected by low substrate solubility, substrate toxicity, inconsistent enzyme expression, insufficient biomass, product degradation, and non-optimized fermentation conditions. An integrated strategy is therefore required to isolate efficient microorganisms, identify transformation products, optimize metabolite yield, and determine whether the derivatives possess greater bioactivity than the parent compound.

3. Aim of the Study

The study aims to isolate and identify microorganisms capable of transforming papaverine into structurally modified pharmaceutical derivatives, optimize the biotransformation process, characterize the resulting metabolites, and evaluate their biological activities.

4. Research Objectives

1. To isolate morphologically diverse fungi, yeasts, and bacteria from medicinal-plant-associated environmental samples.
2. To screen the microbial isolates for their ability to transform papaverine into new metabolites.
3. To identify the most efficient microbial isolate through morphological, biochemical, and molecular methods.
4. To optimize the major biotransformation variables using statistical experimental design.
5. To purify and structurally characterize the principal papaverine derivatives.

5. Research Hypotheses

H1: At least one environmental microbial isolate will transform papaverine into one or more detectable derivatives.

H2: Fermentation conditions will significantly influence substrate conversion and metabolite yield.

H3: Statistical optimization will produce a significantly higher metabolite yield than the unoptimized

INTERNATIONAL JOURNAL OF EXPLORING EMERGING TRENDS IN ENGINEERING
Peer-Reviewed, Refereed, Indexed and International Journal, https://ijoeete.com/
|ISSN No. 2394-0573 |Volume: 11, Issue: 3 | July – September 2024

fermentation process.

6. Materials and Methods

6.1 Research Design

The investigation will follow an experimental laboratory design consisting of four sequential stages:

Stage	Main activity	Expected output
I	Environmental sampling and microbial isolation	Pure fungal, yeast, and bacterial cultures
II	Primary and secondary biotransformation screening	Selection of the most productive isolate
III	Statistical process optimization and scale-up	Increased conversion and product yield
IV	Purification, structural elucidation, and bioactivity testing	Characterized pharmaceutical derivatives

All screening and optimization experiments will be conducted with at least three independent biological replicates.

6.2 Collection of Environmental Samples

Rhizosphere soil, compost, decaying medicinal-plant material, bark, roots, and healthy internal plant tissues will be collected from selected medicinal-plant cultivation areas. Samples will be transferred into sterile containers, labelled according to location and source, and processed under aseptic conditions.

For endophytic isolation, plant tissues will be washed and surface-sterilized using sequential treatments with ethanol and sodium hypochlorite, followed by rinsing with sterile distilled water. The final rinse water will be inoculated onto control plates to verify the effectiveness of surface sterilization.

6.3 Isolation of Microorganisms

Soil and compost samples will be serially diluted in sterile physiological saline. Appropriate dilutions will be inoculated onto potato dextrose agar for fungi, yeast extract peptone dextrose agar for yeasts, and nutrient or tryptic soy agar for bacteria.

Plates will be incubated under conditions suitable for the targeted microbial groups. Colonies showing distinct colour, morphology, texture, growth rate, sporulation, or pigmentation will be repeatedly subcultured until pure cultures are obtained.

A minimum of 50–60 morphologically distinct isolates should be retained for primary screening. Pure fungal isolates will be maintained on agar slants at 4°C and as glycerol stocks at −80°C. Bacterial and yeast isolates will similarly be preserved in suitable cryoprotective media.

6.4 Model Substrate

Papaverine or papaverine hydrochloride of analytical purity will be used as the model organic substrate. A sterile stock solution will be prepared in dimethyl sulfoxide or another validated solvent. The final solvent concentration in fermentation cultures should remain sufficiently low to avoid microbial growth inhibition.

A preliminary substrate-tolerance experiment will be conducted using several papaverine concentrations, for example 25, 50, 100, 200, and 300 mg/L. Microbial growth will be compared with solvent controls to identify a suitable concentration for screening.

6.5 Primary Biotransformation Screening

Each fungal or bacterial isolate will be inoculated into an appropriate liquid medium and incubated to establish active biomass. Papaverine will then be added aseptically. The cultures will be incubated under shaking conditions for five to seven days.

The following controls will be included:

- Microorganism without papaverine
- Papaverine in sterile uninoculated medium
- Solvent control
- Heat-inactivated biomass with papaverine
- Medium-only control

Aliquots will be collected at predetermined intervals. Samples will be extracted using ethyl acetate or another validated organic solvent. The organic layer will be concentrated and initially analysed by thin-layer chromatography.

The appearance of new chromatographic bands accompanied by a decrease in the parent papaverine band will indicate possible biotransformation.

6.6 Secondary Screening by HPLC and LC–MS

Promising cultures identified through thin-layer chromatography will be subjected to high-performance liquid chromatography with diode-array detection. Substrate disappearance and the appearance of new peaks will be monitored relative to the controls.

Transformation efficiency will be calculated as:

$$\text{Conversion (\%)} = \frac{C_0 - C_t}{C_0} \times 100$$

where C_0 is the initial papaverine concentration and C_t is the remaining concentration after incubation.

Liquid chromatography–mass spectrometry will be used to determine the molecular masses of transformation products. Isolates will be ranked according to:

1. Papaverine conversion percentage
2. Number and uniqueness of metabolite peaks
3. Titer of the principal product
4. Reproducibility among biological replicates
5. Stability of the metabolite during extended incubation

The isolate producing the highest concentration of a stable and potentially novel metabolite will be selected for further investigation.

6.7 Identification of the Selected Microorganism

The selected fungal isolate will initially be characterized using colony morphology, microscopic structures, pigmentation, spore morphology, and growth pattern. Molecular identification will be conducted by amplifying and sequencing the internal transcribed spacer region.

For bacterial isolates, genomic DNA will be extracted and the 16S ribosomal RNA gene will be amplified and sequenced. The resulting sequence will be compared with validated reference sequences. Phylogenetic analysis may be performed to establish the relationship between the isolate and its closest relatives.

The identified strain should be deposited in an institutional or recognized microbial culture collection before publication.

6.8 Preliminary Optimization

One-factor-at-a-time experiments will be used to establish appropriate ranges for the following variables:

- Initial pH
- Incubation temperature
- Papaverine concentration
- Inoculum size
- Agitation speed
- Carbon source
- Nitrogen source

- Fermentation time
- Time of substrate addition

This preliminary stage will identify variables with the strongest effects and prevent unsuitable ranges from being included in the statistical design.

6.9 Statistical Optimization

Response surface methodology using a Box–Behnken or central composite design will be employed. Four major factors may be selected, such as:

Factor	Suggested range
Initial pH	5.0–8.0
Temperature	24–34°C
Papaverine concentration	50–250 mg/L
Incubation time	48–144 hours

The main response variables will be:

- Papaverine conversion percentage
- Principal metabolite concentration in mg/L
- Molar product yield
- Selectivity toward the desired metabolite

A second-order polynomial model will be fitted to the experimental data. Analysis of variance will determine the significance of individual factors, interaction terms, and quadratic effects. Model adequacy will be examined through the coefficient of determination, adjusted coefficient of determination, lack-of-fit test, residual distribution, and predicted-versus-observed plots.

Response surface methodology has previously been applied to optimize microbial transformation processes such as the conversion of L-tyrosine into L-DOPA, demonstrating its usefulness for evaluating interactions among culture variables rather than modifying each variable separately.

6.10 Model Validation and Scale-Up

The predicted optimum conditions will be experimentally validated in triplicate. The observed metabolite concentration will be compared with the model prediction.

Following validation, the process will be scaled from shake flasks to a larger fermentation vessel. Dissolved oxygen, pH, biomass formation, substrate concentration, and product concentration will be monitored during fermentation. Samples collected at regular intervals will establish the kinetics of substrate consumption and product formation.

6.11 Extraction and Purification

At the end of fermentation, microbial biomass will be separated by filtration or centrifugation. The culture broth and biomass will be extracted separately because intracellular accumulation may occur.

The crude extract will be fractionated through one or more of the following:

- Silica-gel column chromatography
- Solid-phase extraction
- Sephadex chromatography
- Preparative thin-layer chromatography
- Semi-preparative reversed-phase HPLC

Purity will be assessed through analytical HPLC. A purity level of at least 95% should be targeted before detailed

biological evaluation.

6.12 Structural Characterization

The chemical structure of each major metabolite will be established using:

- High-resolution electrospray mass spectrometry
- Ultraviolet-visible spectroscopy
- Fourier-transform infrared spectroscopy
- One-dimensional $^{1}H$and ^{13}CNMR
- DEPT spectroscopy
- Two-dimensional COSY, HSQC, HMBC, and NOESY spectroscopy

Published papaverine transformation studies have used mass spectrometry and multidimensional NMR to differentiate reduced, demethylated, hydroxylated, oxidized, and N-oxide metabolites.

6.13 α-Glucosidase Inhibition Assay

The antidiabetic potential of papaverine and its derivatives will be examined through an α-glucosidase inhibition assay. The enzyme will be incubated with different concentrations of each test compound before addition of the chromogenic substrate.

Acarbose will serve as the positive control. Percentage inhibition will be calculated relative to the solvent control, and the concentration producing 50% inhibition will be determined through nonlinear regression.

6.14 Pancreatic Lipase Inhibition Assay

Pancreatic lipase inhibition will be measured using a suitable chromogenic substrate. Papaverine, purified derivatives, and orlistat will be evaluated under identical conditions.

Lower half-maximal inhibitory concentrations will indicate stronger enzyme inhibition. The experiment will be performed in triplicate on at least three separate occasions.

6.15 Protein Tyrosine Phosphatase 1B Assay

Where facilities are available, inhibition of protein tyrosine phosphatase 1B will be investigated because this enzyme is involved in the negative regulation of insulin signalling. Papaverine derivatives have previously shown predicted interactions with this target, but experimental enzyme assays are required before pharmacological conclusions can be made.

6.16 Antioxidant Activity

The antioxidant properties of the derivatives will be assessed through at least two complementary assays, such as:

- DPPH radical-scavenging assay
- ABTS radical-cation decolourization assay
- Ferric-reducing antioxidant power assay

The use of more than one assay will reduce the risk of drawing conclusions from a single reaction mechanism.

6.17 Antimicrobial Activity

Minimum inhibitory concentrations will be determined using broth microdilution against selected Gram-positive bacteria, Gram-negative bacteria, and fungi. Representative organisms may include:

- *Staphylococcus aureus*
- *Bacillus subtilis*
- *Escherichia coli*
- *Pseudomonas aeruginosa*
- *Candida albicans*

Appropriate reference antimicrobial agents, sterility controls, growth controls, and solvent controls will be included.

6.18 Preliminary Cytotoxicity and Selectivity

A preliminary safety assessment will be conducted using a non-cancerous mammalian cell line. Cell viability may be measured through the MTT or resazurin reduction assay after exposure to a range of compound concentrations.

The selectivity index will be calculated by comparing the cytotoxic concentration with the concentration required for the intended biological effect. A derivative showing strong enzyme inhibition but high nonspecific cellular toxicity will not be considered a suitable lead.

6.19 Statistical Analysis

Data will be expressed as mean ± standard deviation. Normality and variance assumptions will be examined before inferential analysis. Comparisons among papaverine and its derivatives will be performed using one-way analysis of variance followed by an appropriate multiple-comparison test.

Nonparametric alternatives will be used where assumptions are not satisfied. Differences will be considered statistically significant at $p < 0.05$. Dose–response curves and half-maximal inhibitory concentrations will be calculated through nonlinear regression with confidence intervals.

7. Expected Results and Discussion

7.1 Isolation of Biotransforming Microorganisms

The environmental samples are expected to produce diverse fungal and bacterial isolates. However, only a limited proportion will probably tolerate papaverine and generate detectable metabolites. Differences in transformation capacity may result from variation in cytochrome P450 enzymes, oxidoreductases, demethylases, and other intracellular catalytic systems. Isolates from medicinal-plant-associated environments may be particularly relevant because they are regularly exposed to structurally diverse plant secondary metabolites. Nevertheless, this relationship should be treated as a hypothesis rather than assumed before screening.

7.2 Formation of Papaverine Derivatives

LC–MS analysis may reveal products with molecular masses consistent with hydroxylation, reduction, demethylation, oxidation, or combined reactions. Previous fungal transformation experiments produced 3,4-dihydropapaverine, papaveroline, 7-demethylpapaverine, 6,4′-didemethylpapaverine, papaverine-3-ol, papaverinol, and papaverinol-N-oxide. These compounds demonstrate the broad metabolic accessibility of the papaverine scaffold. The exact products generated by the environmental isolates cannot be predicted with certainty. A mass difference consistent with a known reaction will not by itself establish the product structure. Purification and multidimensional NMR analysis will be required to determine the transformation position and stereochemical configuration.

7.3 Effects of Fermentation Variables

Biotransformation yield is expected to depend strongly on substrate concentration, culture age, pH, temperature, oxygen transfer, and incubation time. Low substrate concentrations may produce insufficient product, whereas excessively high concentrations may inhibit microbial growth or reduce enzyme activity. The timing of substrate addition may also be important. Addition during early growth could inhibit biomass formation, whereas addition after establishment of active biomass may improve conversion. Excessively long incubation may cause secondary metabolism or degradation of the desired derivative.

The optimized conditions are expected to increase both conversion and selectivity. However, maximum substrate disappearance should not automatically be interpreted as maximum pharmaceutical value because complete degradation could produce several low-value metabolites. Optimization should therefore prioritize the titer of the desired product rather than substrate removal alone.

7.4 Pharmaceutical Activity of the Derivatives

Structural modification may alter polarity, solubility, membrane permeability, target binding, and metabolic stability. Hydroxylation may create additional hydrogen-bonding interactions, whereas demethylation may expose phenolic hydroxyl groups. N-oxidation can change electronic distribution and aqueous behaviour. Previous papaverine biotransformation research reported that papaverinol-N-oxide had favourable predicted binding to α-glucosidase, pancreatic lipase, and protein tyrosine phosphatase 1B. However, computational findings alone are insufficient to establish therapeutic activity. The proposed enzyme assays are therefore necessary to determine whether the isolated derivatives truly exhibit stronger biological activity.

A derivative will be considered promising when it demonstrates:

- Reproducible production at a measurable yield
- Confirmed chemical structure and purity
- Lower inhibitory concentration than papaverine
- Acceptable selectivity over unrelated enzymes
- Limited cytotoxicity toward non-cancerous cells
- Sufficient stability during storage and assay conditions

7.5 Scientific Significance

The study may contribute to pharmaceutical biotechnology in three ways. First, it may identify a previously unreported microbial strain with useful catalytic properties. Second, it may produce known papaverine metabolites through a more efficient or selective process. Third, it may generate an unreported derivative with improved biological activity. The platform could later be extended to flavonoids, steroids, terpenoids, chalcones, and other alkaloids. Recent studies have demonstrated that microbial transformations can produce bioactive stilbene methylglucosides, selectively hydroxylated flavonoids, neuroprotective sapogenin derivatives, and regioselectively reduced steroid intermediates.

8. Limitations

Several limitations should be considered. Environmental isolates may produce low metabolite concentrations, mixtures of closely related products, or unstable derivatives. Papaverine may inhibit microbial growth or show limited solubility in aqueous fermentation media. Some metabolites may be difficult to purify in quantities sufficient for complete structural and biological evaluation.

Initial enzyme-inhibition assays provide evidence of biological activity but do not establish therapeutic efficacy. Further studies would require pharmacokinetic assessment, metabolic stability testing, mechanism-of-action experiments, animal studies, and toxicological evaluation.

In addition, a product with strong activity but extremely low fermentation yield may not be industrially practical without strain improvement, enzyme engineering, immobilization, or metabolic pathway modification.

Conclusion

Microbial biotransformation represents a promising strategy for converting papaverine and other structurally complex organic compounds into high-value pharmaceutical derivatives. The proposed study integrates environmental microbial isolation, whole-cell screening, molecular identification, fermentation optimization, chromatographic purification, structural characterization, and biological evaluation.

The use of papaverine as a model substrate provides opportunities to investigate hydroxylation, demethylation, reduction, oxidation, and N-oxide formation. Statistical optimization is expected to improve metabolite yield and reproducibility, while targeted α-glucosidase, pancreatic lipase, protein tyrosine phosphatase 1B, antioxidant, antimicrobial, and cytotoxicity assays will determine whether structural modification produces genuine biological improvement.

The work may identify useful microbial biocatalysts and generate derivatives suitable for subsequent pharmaceutical development. Nevertheless, claims regarding therapeutic value should only be made after experimental confirmation, safety evaluation, and mechanistic validation.

References

Eliwa, D., Kabbash, A., El-Aasr, M., Tawfik, H. O., Batiha, G. E.-S., Mahmoud, M. H., De Waard, M., Eldehna, W. M., & Ibrahim, A.-R. S. (2023). Papaverinol-N-oxide: A microbial biotransformation product of papaverine with potential antidiabetic and antiobesity activity unveiled with in silico screening. *Molecules, 28*(4), 1583. doi:10.3390/molecules28041583.

Gurme, S. T., Surwase, S. N., Patil, S. A., Jadhav, S. B., & Jadhav, J. P. (2013). Optimization of biotransformation of L-tyrosine to L-DOPA by *Yarrowia lipolytica* NCIM 3472 using response surface methodology. *Indian Journal of Microbiology, 53*(2), 194–198. doi:10.1007/s12088-012-0346-z.

Hu, B., Zhao, X., Zhou, J., Li, J., Chen, J., & Du, G. (2023). Efficient hydroxylation of flavonoids by using whole-

cell P450 sca-2 biocatalyst in *Escherichia coli*. *Frontiers in Bioengineering and Biotechnology, 11*, 1138376. doi:10.3389/fbioe.2023.1138376.

Jan, M., Yue, S.-J., Deng, R.-X., Nie, Y.-F., Zhang, H.-Y., Hao, X.-R., Wang, W., Hu, H.-B., & Zhang, X.-H. (2023). *Aspergillus sclerotiorum* whole-cell biocatalysis: A sustainable approach to produce 3-hydroxy-phenazine-1-carboxylic acid from phenazine-1-carboxylic acid. *Fermentation, 9*(6), 579. doi:10.3390/fermentation9060579.

Krawczyk-Łebek, A., Dymarska, M., Janeczko, T., & Kostrzewa-Susłow, E. (2022). 4′-Methylflavanone glycosides obtained using biotransformation in entomopathogenic filamentous fungi cultures as potential anticarcinogenic, antimicrobial, and hepatoprotective agents. *International Journal of Molecular Sciences, 23*(10), 5373. doi:10.3390/ijms23105373.

Küçüksolak, M., Üner, G., Ballar Kırmızıbayrak, P., & Bedir, E. (2022). Neuroprotective metabolites via fungal biotransformation of a novel sapogenin, cyclocephagenol. *Scientific Reports, 12*, 18481. doi:10.1038/s41598-022-22799-5.

Melnyk, N., Popowski, D., Strawa, J. W., Przygodzińska, K., Tomczyk, M., Piwowarski, J. P., & Granica, S. (2024). Skin microbiota metabolism of natural products from comfrey root (*Symphytum officinale* L.). *Journal of Ethnopharmacology, 318*, 116968. doi:10.1016/j.jep.2023.116968.

Peng, Y., Huan, Y., Chen, J.-J., Chen, T.-J., Lei, L., Yang, J.-L., Shen, Z.-F., Gong, T., & Zhu, P. (2023). Microbial biotransformation to obtain stilbene methylglucoside with GPR119 agonistic activity. *Frontiers in Microbiology, 14*, 1148513. doi:10.3389/fmicb.2023.1148513.